EC
DOVA

EcoR1 Capital’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

EcoR1 Capital’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-429,729
Closed -$11.7M – 47
2018
Q1 		$11.7M Buy
+429,729
New +$12.9M 1.17% 20

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

EcoR1 Capital's DOVA Position: Q2 2018 in Review

EcoR1 Capital sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2018, closing a stake of 429,729 shares — an estimated $11.7M sold.

EcoR1 Capital first reported a position in DOVA in Q1 2018 and held it in 1 quarter. The position peaked at $11.7M in Q1 2018. 60 funds tracked by Wall St. Rank hold DOVA as of Q2 2018.

  • EcoR1 Capital reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • EcoR1 Capital sold 429,729 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $11.7M.
  • EcoR1 Capital first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • EcoR1 Capital's Dova Pharmaceuticals, Inc. Common Stock position peaked at $11.7M in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.